BiotechTube

Clazosentan + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aneurysmal Subarachnoid Hemorrhage

Conditions

Aneurysmal Subarachnoid Hemorrhage

Trial Timeline

Dec 14, 2007 → Jul 13, 2010

NCT ID
NCT00558311

About Clazosentan + Placebo

Clazosentan + Placebo is a phase 3 stage product being developed by Idorsia for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00558311. Target conditions include Aneurysmal Subarachnoid Hemorrhage.

What happened to similar drugs?

0 of 3 similar drugs in Aneurysmal Subarachnoid Hemorrhage were approved

Approved (0) Terminated (1) Active (2)
❌Clazosentan 5 m/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 3
🔄Clazosentan + PlaceboIdorsiaPhase 3
🔄GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03585270Phase 3Completed
NCT00558311Phase 3Completed

Competing Products

8 competing products in Aneurysmal Subarachnoid Hemorrhage

See all competitors
ProductCompanyStageHype Score
erythropoietin betaRochePhase 2
35
DenosumabAmgenPhase 2
31
ClazosentanIdorsiaPhase 2
29
Clazosentan 5 m/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 3
26
Clazosentan + PlaceboIdorsiaPhase 3
34
Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 2
29
GTX-104 + Nimodipine CapsulesGrace TherapeuticsPhase 1
19
GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3
34